Healthcare / BiotechnologyBSE
$1521.00
-168.95 (-10.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $34.4M · quality 39.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
56/100
C
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.6B
P/E
23.2x
↑EV/EBITDA
11.0x
↓ROE
10.2%
↑Gross Margin
34.8%
↓Debt/Equity
0.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.0%
FCF CAGR
—
FCF margin
5.6%
FCF / Net income
0.93x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.37B · net income $201.1M · FCF $187.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.37B | $3.37B | $3.00B | $3.13B | $3.47B |
| Net Income | $201.1M | $201.1M | $90.9M | $114.6M | $253.2M |
| EBITDA | $496.4M | $496.4M | $347.4M | $338.1M | $484.4M |
| EPS | 66.51 | 66.51 | 30.08 | 37.92 | 83.76 |
| Gross Margin | 34.8% | 34.8% | 30.3% | 27.1% | 25.2% |
| Operating Margin | 8.9% | 8.9% | 5.4% | 5.8% | 7.1% |
| Net Margin | 6.0% | 6.0% | 3.0% | 3.7% | 7.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.44 | 0.44 | 0.57 | 0.60 | 0.52 |
| Cash Flow | |||||
| Free Cash Flow | $187.1M | $187.1M | $34.4M | $-338.6M | $-623.9M |
| Returns | |||||
| ROE | 10.2% | 10.2% | 5.1% | 6.8% | 16.6% |
| Valuation | |||||
| P/E | 23.20 | 23.20 | 21.69 | 14.73 | 9.43 |
| EV/EBITDA | 10.99 | 10.99 | 8.56 | 7.93 | 6.55 |
| P/B | 2.34 | 2.34 | 1.12 | 1.00 | 1.57 |
| Growth & Yield | |||||
| Revenue Growth | 12.4% | 12.4% | -4.2% | -10.0% | — |
| EPS Growth | 121.1% | 121.1% | -20.7% | -54.7% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
26.6%
EPS terminal req.
$134.96
Spread vs growth
94.5%
5Y implied EPS CAGR
19.7%
EPS terminal req.
$163.31
Spread vs growth
101.4%
10Y implied EPS CAGR
14.7%
EPS terminal req.
$263.01
Spread vs growth
106.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.2%
Start / end P/E
44.7x → 22.9x
EPS bridge
30.08 → 66.51
Residual
-59.1%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.